Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study.

Autor:	Lukow PB; Institute of Cognitive Neuroscience, University College London, London, UK., Lowther M; Institute of Cognitive Neuroscience, University College London, London, UK., Pike AC; Institute of Cognitive Neuroscience, University College London, London, UK.; Department of Psychology & York Biomedical Research Institute, University of York, York, UK., Yamamori Y; Institute of Cognitive Neuroscience, University College London, London, UK., Chavanne AV; Institute of Cognitive Neuroscience, University College London, London, UK.; Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, INSERM U1299 'Trajectoires Développementales Psychiatrie,' Ecole Normale Supérieure Paris-Saclay, CNRS UMR 9010, Centre Borelli, Gif-sur-Yvette, France.; Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany., Gormley S; Institute of Cognitive Neuroscience, University College London, London, UK., Aylward J; Institute of Cognitive Neuroscience, University College London, London, UK., McCloud T; Institute of Cognitive Neuroscience, University College London, London, UK.; UCL Division of Psychiatry, Maple House, London, UK., Goble T; Institute of Cognitive Neuroscience, University College London, London, UK., Rodriguez-Sanchez J; Institute of Cognitive Neuroscience, University College London, London, UK.; Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK., Tuominen EW; Institute of Cognitive Neuroscience, University College London, London, UK., Buehler SK; Institute of Cognitive Neuroscience, University College London, London, UK., Kirk P; Institute of Cognitive Neuroscience, University College London, London, UK.; Emotion and Development Branch, National Institute of Mental Health, Bethesda, MD, USA., Robinson OJ; Institute of Cognitive Neuroscience, University College London, London, UK.
Jazyk:	angličtina
Zdroj:	Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2024 Oct 04, pp. 2698811241286773. Date of Electronic Publication: 2024 Oct 04.
DOI:	10.1177/02698811241286773
Abstrakt:	Background: Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood. Aims: To investigate the neural correlates of subchronic antidepressant administration. Methods: We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before ( n  = 96) and after subchronic escitalopram ( n  = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo ( n  = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration. Results: Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration. Conclusions: To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin. Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: OJR held an MRC-Proximity to discovery award with Roche (who provide in-kind contributions and have sponsored travel for ACP) regarding work on heart-rate variability and anxiety. He also has completed consultancy work for Peak, IESO digital health, Roche and BlackThorn therapeutics. OJR sat on the committee of the British Association for Psychopharmacology until 2022. ACP sits on the Council for the British Association for Psychopharmacology and has received funding from the Wellcome Trust and Academy of Medical Sciences for unrelated projects. TM is currently employed by the Wellcome Trust. The other authors declare no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu